ESC-sEVs alleviate non-early-stage osteoarthritis progression by rejuvenating senescent chondrocytes via FOXO1A-autophagy axis but not inducing apoptosis.

MLA

Feng, Kai, et al. “ESC-SEVs Alleviate Non-Early-Stage Osteoarthritis Progression by Rejuvenating Senescent Chondrocytes via FOXO1A-Autophagy Axis but Not Inducing Apoptosis.” Pharmacological Research, vol. 209, Nov. 2024, p. 107474. EBSCOhost, https://doi.org/10.1016/j.phrs.2024.107474.

APA

Feng, K., Ye, T., Xie, X., Liu, J., Gong, L., Chen, Z., Zhang, J., Li, H., Li, Q., & Wang, Y. (2024). ESC-sEVs alleviate non-early-stage osteoarthritis progression by rejuvenating senescent chondrocytes via FOXO1A-autophagy axis but not inducing apoptosis. Pharmacological Research, 209, 107474. https://doi.org/10.1016/j.phrs.2024.107474

Chicago

Feng, Kai, Teng Ye, Xuetao Xie, Jiashuo Liu, Liangzhi Gong, Zhengsheng Chen, Juntao Zhang, Haiyan Li, Qing Li, and Yang Wang. 2024. “ESC-SEVs Alleviate Non-Early-Stage Osteoarthritis Progression by Rejuvenating Senescent Chondrocytes via FOXO1A-Autophagy Axis but Not Inducing Apoptosis.” Pharmacological Research 209 (November): 107474. doi:10.1016/j.phrs.2024.107474.